Alexar Therapeutics

NeXeption forms new company Alexar Therapeutics to develop novel LXR agonist portfolio for dermatologic indications
Pharmaceutical Business Review
Sat, 01/4/14 - 04:30 pm
LXR agonists
NeXeption
Alexar Therapeutics